Ignite Creation Date:
2025-12-25 @ 12:59 AM
Ignite Modification Date:
2025-12-27 @ 10:49 AM
Study NCT ID:
NCT07266493
Status:
RECRUITING
Last Update Posted:
2025-12-05
First Post:
2025-11-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Sponsor:
Shanghai Zhongshan Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-01
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2025-11-25
First Submit QC Date:
None
Study First Post Date:
2025-12-05
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-25
Last Update Post Date:
2025-12-05
Last Update Post Date Type:
ESTIMATED